Anne Claire Hardy-Bessard

Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Stéphane Oudard, Eugéniu Banu, Philippe Beuzeboc et al. · Journal of Clinical Oncology · 2005 · 141 citations · Full text

Medicine, Oncology, Pharmacology +15

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

Olivier Colomban, Michel Tod, Alexandra Léary et al. · Clinical Cancer Research · 2019 · 68 citations · Full text

Medicine, Gynecology, Oncology +17

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study

Hugues Bourgeois, Françoise Grudé, P. Solal-Céligny et al. · Annals of Oncology · 2017 · 51 citations · Full text

Medicine, Oncology, Palliative Care +9

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy

Stéphane Oudard, I. Latorzeff, Armelle Caty et al. · JAMA Oncology · 2019 · 33 citations · Full text

Medicine, Oncology, Urology +13

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Karen A. Gelmon, Peter A. Fasching, Fergus J. Couch et al. · European Journal of Cancer · 2021 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17